English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAtrial fibrillation is the most common type of heart rhythm disorder. The Centers for Disease Control and Prevention estimates it affects between 2.7 million and 6.1 million people in the United States. About 40 percent of patients with this condition have intermittent episodes of atrial fibrillation, called paroxysmal atrial fibrillation, which can eventually progress into persistent atrial fibrillation. Patients with atrial fibrillation are five- to seven-times more likely to have a stroke than the general population. Atrial fibrillation also can lead to heart failure.
Paroxysmal atrial fibrillation is typically first treated with anti-arrthythmic drugs; however, improvements in the safety and efficacy of ablation have led to increased interest in ablation as the initial therapy before using drugs. One of these ablation modalities is cryoballoon ablation in which the physician inserts a balloon filled with liquid nitrogen to freeze the heart tissue that is causing the irregular heartbeat.
The STOP AF FIRST trial studied 203 patients with paroxysmal atrial fibrillation, not previously treated with medications, over the course of a year at 24 sites across the U.S. The patients were randomized to receive cryoballoon catheter ablation or standard-of-care medications. At 12 months, 75 percent of the ablation patients were free from atrial fibrillation without additional treatment compared with 45 percent of the medication patients.
“Previous studies have shown success in using ablation early in atrial fibrillation patients, but this is the first to study ablation as the initial therapy early in the AF disease process and the results may signal a shift in how we think about treatment,” said Oussama Wazni, M.D., section head of electrophysiology and pacing at Cleveland Clinic and principal investigator of the study. “Earlier intervention with ablation may keep patients free from atrial fibrillation longer and prevent the disease from progressing into more persistent atrial fibrillation.”
The use of the cryoballoon catheter ablation also was very safe with only two primary safety events (1.9 percent) observed.
The study was sponsored by Medtronic, a maker of the cryoballoon ablation catheter. All analyses were independently confirmed by the Cleveland Clinic Center for Clinical Research.
About Cleveland Clinic
Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. Among Cleveland Clinic’s 67,554 employees worldwide are more than 4,520 salaried physicians and researchers, and 17,000 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,026-bed health system that includes a 165-acre main campus near downtown Cleveland, 18 hospitals, more than 220 outpatient facilities, and locations in southeast Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2019, there were 9.8 million total outpatient visits, 309,000 hospital admissions and observations, and 255,000 surgical cases throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 185 countries. Visit us at clevelandclinic.org. Follow us at twitter.com/ClevelandClinic. News and resources available at newsroom.clevelandclinic.org.
Editor’s Note: Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request.
